Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphoric chloroquine plus standard therapy versus placebo plus standard therapy in severe or critically ill COVID-19
ChiCTR2000029826Phase 4Not yet recruiting
- Sponsor
- Jingzhou Central Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Phosphoric chloroquine group with Placebo group (2 arms). Primary endpoint: Mortality rate. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
chloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029826.